Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation [0.03%]
EPIK-O/ENGOT-ov61主要分析：阿培利塞联合奥拉帕利对比化疗用于BRCA野生型铂耐药或铂难治的高级别浆液性卵巢癌患者的疗效
Panagiotis A Konstantinopoulos,Jae Weon Kim,Gilles Freyer et al.
Panagiotis A Konstantinopoulos et al.
Purpose: Patients with platinum-resistant/platinum-refractory high-grade serous ovarian cancer (HGSOC) without a BRCA mutation have poor prognosis and limited treatment options. We report efficacy and biomarker data from ...
Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia [0.03%]
纳武利尤单抗联合化疗对比单纯化疗治疗转移性鳞状细胞癌的三期临床试验（CheckMate-057）和纳武利尤单抗联合ipiolummab对比化疗治疗转移性非鳞状非小细胞肺癌的三期临床试验（CheckMate-227）：生存分析
Inna M Chen,Julia S Johansen,Susann Theile et al.
Inna M Chen et al.
Reply to: Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT [0.03%]
谨防选择性颈部减量照射在头颈肿瘤治疗中应用过当——对UPGRADE-RT的回复
Sven van den Bosch,Gerjon Hannink,Johannes H A M Kaanders
Sven van den Bosch
Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT [0.03%]
谨防颈部选择性根治区放疗剂量递减：对UPGRADE-RT的回应
Naomi Kiyota,Junki Mizusawa,Sadamoto Zenda et al.
Naomi Kiyota et al.
Response-Adapted Surgical and Radiotherapy De-Escalation in Resectable Cutaneous Squamous Cell Cancer Using Pembrolizumab: The De-Squamate Study [0.03%]
手术和放疗去强化的适应性治疗可切除皮肤鳞状细胞癌：De-Squamate研究
Rahul Ladwa,Jenny H Lee,Margaret McGrath et al.
Rahul Ladwa et al.
Purpose: The high rates of pathologic complete response (pCR) after neoadjuvant immunotherapy have generated interest for a risk adaptive surgical and radiotherapy-free management approach to reduce morbidity in resectabl...
Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma [0.03%]
以磨玻璃样成分为主的肺腺癌患者行 mediastinal 淋巴结清扫的三期临床研究
Yang Zhang,Bin Qian,Qingping Song et al.
Yang Zhang et al.
Purpose: Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non-small cell lung cancer. We aimed to investigate whether no mediastinal LND was noninferior...
Lajos Pusztai,Mariya Rozenblit,Peter Dubsky et al.
Lajos Pusztai et al.
Krina Patel,Thierry Facon
Krina Patel
Reading the Room: A Joint Perspective From a Scientist- and Patient-Partnered Working Group on the Importance of Patient-Centered Language in the Dissemination of Cancer Research [0.03%]
读懂房间里的氛围——来自癌症研究传播中的患者导向性语言的医患合作伙伴关系视角的重要性说明
Cara MacInnis,Kyle Dickinson,Kirsten Efremov et al.
Cara MacInnis et al.
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1 [0.03%]
无驱动基因改变的IV期非小细胞肺癌治疗：ASCO实时指南，第2025.1版
Dwight H Owen,Balazs Halmos,Sonam Puri et al.
Dwight H Owen et al.
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that system...